UK markets open in 6 hours 27 minutes
NIKKEI 225
38,255.73 +53.36 (+0.14%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
79.28 +0.29 (+0.37%) GOLD FUTURES
2,314.90 -7.40 (-0.32%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,111.35 -875.32 (-1.75%)
Lonza Group Ltd (LO3.HM)
Hamburg - Hamburg Delayed price. Currency in EUR
Add to watchlist
At close: 08:01AM CEST
| Previous close | 291.30 |
| Open | 293.40 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 293.40 - 293.40 |
| 52-week range | 291.30 - 293.40 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireNeuroSense Announces First Quarter 2024 Business Update
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
Business WireVertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.
© 2024 Yahoo. All rights reserved.